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BACKGROUND: Long-term trajectories of left ventricular ejection fraction 
(LVEF) in heart failure (HF) patients with preserved EF (HFpEF) remain 
unclear. Our objective was to assess long-term longitudinal trajectories in 
consecutive HFpEF patients and the prognostic impact of LVEF dynamic 
changes over time.
METHODS AND RESULTS: Consecutive ambulatory HFpEF patients 
admitted to a multidisciplinary HF Unit were prospectively evaluated by 
2-dimensional echocardiography at baseline and at 1, 3, 5, 7, 9, and
11 years of follow-up. Exclusion criteria were patients having a previous 
known LVEF <50%, patients undergoing only 1 echocardiogram study, 
and those with a diagnosis of dilated, noncompaction, alcoholic, or toxic 
cardiomyopathy. One hundred twenty-six patients (age, 71±13 years; 
63% women) were included. The main pathogeneses were valvular 
disease (36%) and hypertension (28%). Atrial fibrillation was present in 
67 patients (53%). The mean number of echocardiographies performed 
was 3±1.2 per patient. Locally weighted error sum of squares curves 
showed a smooth decrease of LVEF during the 11-year follow-up that was 
statistically significant in linear mixed-effects modeling (P=0.01). Ischemic 
patients showed a higher decrease than nonischemics. The great majority 
(88.9%) of patients remained in the HFpEF category during follow-up; 
9.5% evolved toward HF with midrange LVEF, and only 1.6% dropped to 
HF with reduced LVEF. No significant relationship was found between LVEF 
dynamics in the immediate preceding period and mortality.
CONCLUSIONS: LVEF remained ≥50% in the majority of patients with 
HFpEF for ≤11 years. Only 1.6% of patients evolved to HF with reduced 
LVEF. Dynamic LVEF changes were not associated with mortality.
ORIGINAL ARTICLE
Heart Failure With Preserved Ejection Fraction 
Infrequently Evolves Toward a Reduced 
Phenotype in Long-Term Survivors
A Long-Term Prospective Longitudinal Study
© 2019 American Heart Association, Inc.









Mar Domingo, MD, PhD
Julio Núñez, MD, PhD










Key Words: ejection fraction ◼ follow-




The main terminology used to describe heart fail-ure (HF) is based on the measurement of left ven-tricular ejection fraction (LVEF). A wide range of 
patients have HF, including those with normal LVEF (typ-
ically considered as ≥50%; HF with preserved ejection 
fraction [HFpEF]) to those with reduced LVEF (typically 
considered as <40%; HF with reduced ejection fraction 
[HFrEF]).1 Patients with an LVEF in the range of 40% 
to 49% represent a gray area, defined in the most re-
cent European Society of Cardiology guidelines as HF 
with midrange LVEF (HFmrEF).1 Patients with HFpEF are 
a heterogeneous group with various underlying patho-
geneses and pathophysiological abnormalities, and the 
diagnosis is more challenging than for HFrEF because 
it largely involves excluding other potential noncardiac 
causes of symptoms suggestive of HF.1,2
Although the proportion of patients with HFpEF 
ranges from 22% to 73%, depending on the defini-
tion,1,2 the long-term LVEF longitudinal trajectories in 
patients with HFpEF are unclear. Most data come from 
retrospective analyses in which subsequent LVEF assess-
ments were clinically driven and thus susceptible to im-
portant indication bias, rather than because of a pro-
spective fixed protocol3,4 and had limited follow-up.3–5 
We recently reported the longitudinal dynamics of LVEF 
in patients with HFrEF and HFmrEF.6 In the current re-
port, our aim was to prospectively assess LVEF longitu-
dinal trajectories in the long term (≤11 years) in a con-
secutive real-life cohort of patients with HFpEF.
METHODS
Study Population
Consecutive ambulatory patients with HFpEF referred to an 
HF clinic between August 2001 and December 2015 were 
considered for the study. The main inclusion criteria were hav-
ing an initial LVEF ≥50%, at least 1 hospital admission for 
HF, and having at least 2 echocardiography measurements 
during the study period. Exclusion criteria were as follows: 
having a previous known LVEF <50% (the so-called HF with 
recovered LVEF), undergoing only 1 echocardiogram (death 
before 1 year of follow-up or not attending the scheduled 
echocardiography tests), and having a diagnosis of dilated, 
noncompaction, alcoholic, or toxic cardiomyopathy.
Planned follow-up visits and scheduled echocardiogram 
tests included a minimum of 1 visit with a nurse every 3 
months and 1 visit with a physician (cardiologist, internist, 
or family physician) every 6 months, as well as optional visits 
with specialists in geriatrics, psychiatry, and rehabilitation. The 
LVEF measurements were prospectively scheduled at baseline, 
1 year afterward, and then every 2 years and were performed 
using 2-dimensional echocardiography by cardiologists who 
were imaging experts. The LVEF was obtained from apical 
2- and 4-chamber views and calculated using the Simpson
method. All echocardiograms were revised for accuracy by
expert staff. During the baseline visit, patients provided writ-
ten consent for the use of their clinical data for research
purposes. The study was performed in compliance with the
law protecting personal data in accordance with the interna-
tional guidelines on clinical investigation of the World Medical
Association Declaration of Helsinki.
Statistical Analysis
Categorical variables were expressed as absolute numbers 
and percentages. Continuous variables were expressed as the 
mean (SD) or median (quartiles Q1–Q3) according to normal 
or non-normal distributions. Normal distribution was assessed 
with normal Q to Q plots. Locally weighted error sum of 
squares (Loess) curves—a nonparametric approach developed 
in 1988—were plotted for the whole cohort.7 Loess curves 
are useful to observe trends or relationships in nonlinear data 
observed over time. Loess moves along data looking at chunks 
at a time, fitting a set of local regression lines computed using 
the observed data (missing values are omitted) and connect-
ing these lines to make a smooth line. Missing data because 
of loss to follow-up were assumed to be at random because 
there was no evidence that not attending the scheduled visit 
had anything to do with LVEF. Locally weighted regression is 
based on a weight function, which gives the greatest weight 
to observations that are the closest to the focal observation.
Statistical analyses of the LVEF change over time were 
performed by linear mixed-effects (LME) modeling, which 
takes into account the group-level structure in the data by 
simultaneously assessing effects within and across groups. 
The LME models incorporate both fixed effects and random 
effects and describe the relationship between a response and 
WHAT IS NEW?
• Left ventricular ejection fraction (LVEF) trajectories
in heart failure with preserved ejection fraction are
not well elucidated.
• Previous data based on clinically driven LVEF mea-
surements may be biased toward a higher pro-
portion of patients with left ventricular functional
deterioration.
• This prospective protocol-fixed LVEF assessment
suggests that heart failure with preserved ejec-
tion fraction infrequently evolves toward an heart
failure with preserved ejection fraction–declined
phenotype.
• Mortality was not associated with a declining LVEF
in the preceding period.
WHAT ARE THE CLINICAL 
IMPLICATIONS?
• Contemporary medical treatments have not sig-
nificantly changed the prognosis of patients with
heart failure with preserved ejection fraction.
• Because longitudinal LVEF assessment does not
seem to play a crucial role in mortality, new treat-
ment targets are necessary, such as comorbidities,
inflammation, vascular stiffness, endothelial dys-
function, and others.
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covariates that have been observed along with the response.8 
In this study, LME models were built using the nlme package9 
to evaluate the effect of time on LVEF change. We hypothe-
sized that there are important individual-level effects and that 
patients have similar rates of change over time; thus, we fit-
ted random intercept LME models. In this type of LME model, 
the measured value of LVEF is assumed to have a set of fixed 
parameters across individuals, but there is a specific random 
effect per individual. Also, we performed mean paired data 
comparisons between each predefined study time point. 
Finally, changes in the LVEF categories established in the 2016 
HF Guidelines of the European Society of Cardiology were 
analyzed between the baseline LVEF and the last obtained 
LVEF for each patient. Statistical analyses were performed 
using SPSS 21 (SPSS, Inc, Chicago, IL) and R (A Language 
and Environment for Statistical Computing) by the R Core 
Team (2017; R Foundation for Statistical Computing, Vienna, 
Austria). For LME models, we used the nlme R package, ver-
sion 3.1-131.1.9 A 2-sided P<0.05 was considered significant. 
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure. J.L. had full access 
to all the data in the study and takes responsibility for its in-
tegrity and the data analysis.
RESULTS
A total of 265 patients with LVEF ≥50% were admit-
ted to the outpatient HF Unit. Seventeen patients were 
excluded because of a previous known LVEF <50%, 
106 were excluded because they had only 1 echocar-
diogram study (45 died during the first year, and 61 did 
not attend the scheduled echocardiography exams), and 
15 were excluded because of an etiology diagnosis con-
sidered a phenotype not related to HFpEF (3 dilated, 4 
noncompaction, 3 alcoholic, and 5 drug-derived cardio-
myopathies). Table I in the Data Supplement compared 
Table. Demographic, Clinical, Echocardiographic Characteristics and 
Treatment of Patients at Baseline and Treatments During Follow-Up
Total Cohort N
Age, y 71±13 126
Women, n (%) 79 (62.7) 126
White 125 (99.2) 126
Pathogenesis 126
 Ischemic heart disease 18 (14.3)
 Hypertensive 35 (27.8)
 Hypertrophic cardiomyopathy 15 (11.9)
 Valvular 45 (35.7)
 Other 13 (10.3)
HF duration, mo 12 (2.8–36.5) 126
≥1 HF admission in previous year 87 (69) 126
NYHA class 126
 I 9 (7.1)
 II 67 (53.2)
 III 48 (38.1)
 IV 2 (1.6)
LVEF, % 63±8 126
LV end-diastolic diameter, mm 49.2±7 120
LV end-systolic diameter, mm 32.1±7.6 118
IVS, mm 13.4±3.2 102
PW, mm 12.2±2 102
LA diameter, mm 50 (45–56) 124
PAP, mm Hg 49±14 98
Mitral regurgitation, n (%) 126
 Mild 62 (50)
 Moderate 22 (17)
 Severe 16 (13)
Hypertension, n (%) 94 (74) 126
Diabetes mellitus, n (%) 50 (40) 126
COPD, n (%) 17 (13.5) 126
Peripheral arteriopathy, n (%) 11 (8.7) 126
Atrial fibrillation, n (%) 67 (53) 126
Anemia, n (%)* 64 (50.8) 123
Renal insufficiency, n (%)† 70 (55.6) 124
Blood pressure, mm Hg 138.1±26.3 126
Heart rate, bpm 70.1±14.3 126
BMI, kg/m2 27.1 (24.3–31) 125
NT-proBNP, ng/L 1490 (628–2797) 96
Treatment (baseline), n (%)
 ACE inhibitor or ARB 91 (72.2) 126
 β-Blocker 68 (54) 126
 MRA 27 (21.4) 126
 Loop diuretic 99 (78.6) 126
 Digoxin 31 (24.6) 126
 ICD 3 (2.4) 126
(Continued )
Treatment (F-U), n (%)
 ACE inhibitor or ARB 88 (70) 126
 β-Blocker 97 (77) 126
 MRA 69 (54.8) 126
 Loop diuretic 116 (92.1) 126
 Digoxin 54 (42.9) 126
 ICD 5 (4) 126
Data represent the mean±SD, median (quartiles Q1–Q3), or n (%). ACE 
indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; F-U, 
follow-up; HF, heart failure; ICD, implantable cardioverter-defibrillator; IVS, 
interventricular septum; LA, left atrium; LV, left ventricle; LVEF, left ventricular 
ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New 
York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; 
PAP, pulmonary artery pressure; PW, posterior wall; and WHO, World Health 
Organization.
*According to WHO criteria (<13 g/dL in men and <12 g/dL in women).
†Estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology




the studied cohort and patients who died during the 
first year of follow-up and those who did not attend the 
scheduled echocardiography exams. Patients who died 
during the first year had a significantly worse clinical 
profile, whereas those who did not come back for their 
repeat echocardiogram were clinically similar to the in-
cluded patients. Thus, 126 patients (age, 71±13 years; 
63% women) were finally included in the present report. 
The main HF pathogeneses were valvular disease (36%) 
and hypertensive cardiomyopathy (28%; Table). Sixty-
seven patients (53%) were in atrial fibrillation. Treat-
ments at baseline and during follow-up are depicted in 
the Table. Notably, β-blocker, mineralocorticoid receptor 
antagonists, and digoxin were significantly increased 
during follow-up. Thirteen electrical cardioversions and 
3 atrial ablations were performed, but at the last fol-
low-up, only 3 such patients remained in sinus rhythm. 
Sixteen revascularization procedures were performed in 
10 ischemic patients. Figure I in the Data Supplement 
shows the distribution of echocardiograms performed 
on the patients. The LVEF measurements were obtained 
from 126, 108, 73, 43, 22, 11, and 8 patients at the pre-
defined time points, accounting for 100%, 86%, 82%, 
75%, 73%, 85%, and 89% of the patients alive at each 
time point. The mean number of echocardiography mea-
surements performed was 3±1.3 per patient. All-cause 
mortality at 11 years was 89%. Table II in the Data Sup-
plement shows the causes of death for the whole cohort.
Figure  1A shows the Loess curve of the LVEF dy-
namic trajectory of the entire cohort at every study 
time point. A smooth decrease was observed during 
follow-up. Although numerically small, the LME model 
showed that changes in LVEF were statistically signifi-
cant during the 11-year follow-up (P=0.01). The mean 
LVEF at each study time point was 63±8%, 62±9%, 
61±9%, 61±7%, 61±7%, 61±8%, and 58±6%. Fig-
ure II in the Data Supplement shows violin plots of 
LVEF at each study time point. Paired data compari-
sons showed no statistical differences between study 
periods (Table III in the Data Supplement). Table IV in 
the Data Supplement shows trajectories of other avail-
able echocardiography data beyond LVEF. Remark-
ably, the great majority of patients remained in the 
HFpEF category (88.9%) at their last echocardiogra-
phy, whereas 9.5% went down to HFmrEF and 1.6% 
dropped to HFrEF (or HFpEF declined; Figure 1B). None 
of the patients of ischemic pathogenesis declined to 
HFrEF, but 27.8% declined to HFmrEF, versus 6.6% of 
nonischemic pathogeneses (P=0.005). Eight of the 12 
patients (67%) who declined to HFmrEF had a base-
line LVEF between 50% and 55%; the 2 patients who 
went down to HFrEF had a baseline LVEF ≥65%. As 
triggers for LVEF declining in such patients, 5 experi-
enced a new myocardial infarction, 1 developed severe 
senile amyloidosis, 1 had breast neoplasm metastases, 
1 developed permanent atrial fibrillation, 1 developed 
severe renal insufficiency, and 2 patients with severe 
valvular disease were rejected for surgery, with pro-
gressive deterioration.
The patients with HFpEF with an ischemic pathogene-
sis had an ominous outcome; all died within 5 years, and 
they had a steeper declining LVEF slope during the first 5 
years (Figure 2); in the LME model, a significant interaction 
was found between ischemic pathogenesis and LVEF tra-
jectory (P=0.03). A significant interaction was also found 
between LVEF trajectories and sex (P=0.04; Figure 3A) but 
not with age (≤75 versus >75 years; P=0.75), Figure 3B) 
or HF duration (≤1 versus >1 year; P=0.6; Figure 3C). We 
did not find a relationship between worse LVEF dynamics 
in the preceding study period (changes between the 2 
previous LVEF values) and mortality (Figure 4A) or for the 
different trajectories between survivors and nonsurvivors 
during follow-up (P for interaction, 0.69), Figure 4B). Ta-
bles V to X in the Data Supplement show LME model 
formulas and regression results.
DISCUSSION
This is the first long-term assessment of LVEF trajecto-
ries using a prespecified and fixed prospective echocar-
diography protocol in patients with HFpEF. Two main 
findings emerged: (1) the LVEF dynamics in HFpEF did 
Figure 1. Left ventricular ejection fraction (LVEF) trajectories and 
changes during follow-up.  
A, Loess curve of the LVEF longitudinal trajectory for the total cohort; P=0.01. 
Shaded regions displayed around curves represent the 95% CI. B, Changes 
from heart failure with preserved ejection fraction (HFpEF) at baseline to heart 
failure with midrange LVEF (HFmrEF) or heart failure with reduced ejection 
fraction (HFrEF) at the last observation for every patient.
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not show significant changes toward reduced HF phe-
notypes during follow-up in the great majority of long-
term survivors, although a smooth decline in LVEF was 
observed; and (2) the LVEF dynamics in the immediate 
preceding period were not associated with mortality, 
which, nevertheless, was unacceptably high (89% at 11 
years). These data showed relevant differences in the 
LVEF trajectories in patients with HFrEF and HFmrEF,6 as 
well as with previous studies that examined LVEF trajec-
tories in HFpEF subjects in a retrospective and clinically 
driven manner.3,4
Regarding LVEF trajectories in different HF settings, 
we recently reported significant LVEF changes during 
follow-up in patients with depressed LVEF (EF <50%). 
In brief, we reported a steep LVEF increase during the 
first year, a plateau during the decade after, and a 
slow decline thereafter.6 In these patients, LVEF trajec-
tories showed significant differences according to sex, 
ischemic pathogenesis, and HF duration.6 In the cur-
rent HFpEF study, LVEF trajectories showed a smooth 
decrease but remained markedly above 50% during 
follow-up (Figure 1A) in the whole cohort. Remarka-
bly, a significant interaction was found between LVEF 
trajectories and ischemic pathogenesis and sex. The 
differences found between LVEF trajectories in differ-
ent HF phenotypes (namely HF with depressed or pre-
served LVEF) were not unexpected given the distinct 
pathobiology underlying both conditions, patterns of 
ventricular remodeling, and clinical characteristics.10–13 
In addition, huge differences have been reported for 
the effects of treatments on LVEF trajectories and out-
comes as medications that produce unequivocal ben-
efits in patients with HFrEF have not improved patients 
with HFpEF.
Previous reports have examined LVEF trajectories 
in HFpEF. Dunlay et al,3 in a retrospective community-
based cohort of incident HF patients, found that an 
LVEF decline to <50% was found in 38.5% of patients 
with HFpEF during follow-up, and 25.1% had a decline 
in LVEF to <40%. On average, the authors reported 
an LVEF decrease of 5.8% during 5 years with greater 
declines in older individuals and those with coronary 
disease. A major limitation of this study, pointed out by 
the authors, is that “all echocardiograms were obtained 
at the discretion of the patient’s providers rather than at 
prespecified intervals.” This is a source of potential bias 
with ejection fraction assessment being influenced by 
clinical status, age, provider, and therapeutic era.3 In-
deed, the authors highlighted the need for prospective 
longitudinal studies, such as that reported here. Clarke 
et al4 studied a cohort of patients with HFpEF with a 
primary hospital discharge diagnosis of HF and 2 LVEF 
tests over 30 days apart. For similar patients with HFpEF, 
after 5 years of follow-up, there was a 15% probabil-
ity they would remain as HFpEF and a 33% probability 
they would decline to HFrEF. Again, the authors recog-
nized limitations because these data were observational 
and the times of ascertainments of LVEF were clinically 
driven rather than following a fixed prospective proto-
col. In this study, patients were more likely to have LVEF 
measured when they were less well, resulting in an up-
ward bias in the estimated hazard for transitioning from 
HFpEF to HFrEF or less likely to have the LVEF measured 
when they were nearing end of life, which could result 
in a downward bias.
In contrast to these previously discussed reports, and 
more in agreement with our data, is the report by Tsuji et 
al5 in the CHART-2 study (Chronic Heart Failure Registry 
Figure 2. Loess spline curves for the long-term left ventricular ejection fraction (LVEF) trajectories based on the pathogenesis of heart failure.  
Ischemic (orange) vs nonischemic (blue); in the linear mixed-effects model, a significant interaction was found between ischemic and LVEF trajectory (P=0.03). 
Shaded regions displayed around curves represent the 95% CI.
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Figure 3. Loess spline curves for the long-term left ventricular ejection fraction (LVEF) trajectories based on several characteristics of patients.  
A, Sex: women (orange) vs men (blue); P=0.04 for the interaction between sex and LVEF trajectory in the linear mixed-effects (LME) model. B, Age: ≤75 y (or-
ange) vs >75 y (blue); P=0.75 for the interaction between age group and LVEF trajectory in the LME model. C, Duration of heart failure (HF): ≤12 mo (orange) 
vs >12 mo (blue); P=0.6 for the interaction between HF duration group and LVEF trajectory in the LME model. Shaded regions displayed around curves repre-
sent the 95% CI.
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and Analysis in the Tohoku District 2), although this study 
is limited by a shorter follow-up, with prospective LVEF 
assessments at baseline, 1, 2, and 3 years. These authors 
found that patients with HFpEF transitioned to HFmrEF 
and HFrEF by 8% and 2% at 1 year and by 8% and 4% 
at 3 years, respectively.5 These results confirm that the 
LVEF trajectories in HFpEF, when assessed according to 
a fixed protocol, infrequently evolve toward an HFpEF-
declined phenotype. Differences in cohorts’ characteris-
tics may also account, at least in part, for the differences 
found relative to retrospective studies.
Of interest, Ueda et al,14 in a retrospective analysis 
of 100 patients admitted because of acute HF, found 
that an initial LVEF ≤55% was key for transitioning from 
HFpEF to HFmrEF (10 of 13 versus 1 of 87 with initial 
LVEF >55%; P<0.001). In our prospective assessment, 
we also found that 8 of 12 patients (67%) who tran-
sitioned to HFmrEF had a baseline LVEF ≤55%. Using 
50% as the cutoff for HFpEF is arbitrary and eventu-
ally the range of 50% to 55% LVEF may represent, at 
least in some patients, an incipient degree of systolic 
dysfunction rather than a true HFpEF phenotype. In-
deed normal LVEF by 2-dimensional echocardiography 
is probably the nearest to 55% than 50%,15,16 and most 
LVEF follow-up studies have been performed by 2-di-
mensional echocardiogram.
The value of LVEF dynamics in predicting mortality 
risk also differed between depressed and preserved 
Figure 4. Trajectories and changes in left ventricular ejection fraction (LVEF) and survival.  
A, Changes between the last 2 echocardiograms before the analyzed study period according to vital status. Orange represents those patients who died in the 
subsequent study period, and blue represents those who survived for the entire subsequent period. B, Loess spline curves of long-term LVEF trajectories relative to 
vital status during follow-up. Patients who died during follow-up (orange) vs patients alive at the end of follow-up (blue); P=0.69 for the interaction between vital 
status at the end of follow-up and LVEF trajectory. Shaded regions displayed around curves represent the 95% CI.
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HF phenotypes. In our previous study, we found that 
patients with LVEF <50% who died had worse LVEF 
dynamics in the preceding study period,6 whereas we 
did not find such a relationship in the present HFpEF 
cohort. Differences in the causes of death might play 
an important role in this discrepancy. Noncardiovascular 
death occurred in ≈15% of all patients with depressed 
HF in our previous study, whereas in the present HFpEF 
cohort, >25% of patients died from noncardiovascular 
causes. As the longitudinal LVEF assessment does not 
seem to play a crucial role in mortality in HFpEF, new 
treatment targets are needed, including comorbidities, 
inflammation, vascular stiffness, endothelial dysfunc-
tion, and others.
This study is not without limitations. The study 
sample size is limited, and patients were treated at 
a specific multidisciplinary HF clinic in a tertiary-care 
hospital, with patients referred after at least 1 hos-
pital admission or with a history of difficult manage-
ment. That means they are highly selected patients, so 
we cannot disregard selection bias by disease sever-
ity. LVEF was assessed by transthoracic echocardiog-
raphy in routine clinical care. However, in the current 
study, all echocardiograms were scheduled and ana-
lyzed prospectively and at prespecified intervals and 
not at the discretion of the patient’s physician. We 
acknowledge that the intraobserver and interobserver 
variabilities of echocardiogram-derived LVEF are ≈5%. 
However, we assume that such variability was ran-
domly distributed during follow-up. Further, contrast 
echocardiography may be superior in the evaluation 
of left ventricular remodeling parameters. However, it 
is infrequently used in clinical practice, usually only in 
selected patients. Three-dimensional echocardiogra-
phy and cardiac magnetic resonance imaging would 
evaluate left ventricular function and volumes more 
precisely, but they are not broadly used in clinical prac-
tice and even less so in HFpEF. As in all published stud-
ies of changes in left ventricular function during fol-
low-up, our analyses were performed in completers, 
that is, patients with data available from both baseline 
and at least the 1-year echocardiography. We cannot 
fully discard that excluded patients eventually experi-
enced a drop in their LVEF, but we found no evidence 
to support such possibility. Nevertheless, these results 
can only apply to subjects on whom we had long-term 
data. The limited proportion of patients with HF of 
ischemic pathogenesis (14%) could influence the re-
ported data because their trajectories showed a sig-
nificantly steeper slope without reaching the HFrEF 
cut-point. Finally, we cannot fully exclude some bias 
in the Loess spline curves due to dropout because we 
could not statistically distinguish between autono-
mous time trends and pseudo upward trends due to 
successive dropouts (because of fatalities) with lower 
initial LVEF values. Missing values because of patients’ 
loss to follow-up were assumed to be at random. Fur-
thermore, Loess spline curve estimations at the end of 
follow-up are less robust because of the limited num-
ber of patients.
CONCLUSIONS
LVEF remained ≥50% in the majority of patients with 
HFpEF for ≤11 years, whereas 9.5% of patients evolved 
to HFmrEF and 1.6% to HFrEF during long-term fol-
low-up. In patients with HFpEF of ischemic pathogene-
sis, the evolution to HFmrEF reached 27.8% during fol-
low-up. No significant relationship was found between 
the LVEF trajectory or LVEF dynamics in the immediate 
preceding period and mortality.
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